RxDoctor Payments Data

Ramses Ribot, MD

Neurology · Miami, FLNPI 1851547764

Payments from drug & device makers

$6,965in general payments, 2019–2025

Across 66 payments — averaging $105.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$4K
  • Medtronic$1K
  • Neuropace, Inc.$563
  • Jazz Pharmaceuticals Inc.$492
  • UCB, Inc.$472
  • Livanova USA, Inc.$194
  • plus $236 from 4 others

What the payments were for

  • Speaking & faculty fees$2,75039%
  • Travel & lodging$1,25418%
  • Food & beverage$2,96143%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,965 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$38,278
Medicare patients
151
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)54$369,263
FycompaPerampanel52$81,586
TopamaxTopiramate27$77,674
ValtocoDiazepam25$71,781
XcopriCenobamate39$67,466
AptiomEslicarbazepine Acetate31$67,420
LamictalLamotrigine45$66,250
KeppraLevetiracetam15$48,536
VimpatLacosamide42$46,576
BriviactBrivaracetam24$35,530
OnfiClobazam11$33,412
Keppra XrLevetiracetam12$32,778
Lacosamide168$22,901
Clobazam236$21,956
Depakote ErDivalproex Sodium27$15,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$472$82,10666 claims
Eisai Inc.Fycompa$25$81,58652 claims
Neurelis, Inc.Valtoco$146$71,78125 claims
Sunovion Pharmaceuticals Inc.Aptiom$49$67,42031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →